Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies

NCT02636855 is registered in ClinicalTrials.gov with Adaptimmune as lead sponsor.

NCT NCT02636855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02636855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Lead sponsor
Adaptimmune
Phase
Observational
Overall status
Completed
Start date
December 31, 2015
Completion date
June 28, 2024
Enrollment
9,122 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

solid and hematological malignancies